Company*
(Country; Symbol)

University/
Nonprofit@

Type Of
Agreement

Product Area

Details (Date)


ACE
BioSciences
A/S*
(Denmark)

U.S. Naval Medical Research Center

Collaboration

Deal to progress ACE's ACE393 through Phase II trials

The vaccine is being developed for treating travelers' diarrhea caused by Campylobacter infection; terms of the deal were not disclosed(9/7)

Acologix Inc.*

University of Maryland at Baltimore

License agreement

Acologix licensed technology for potential treatment of interstitial cystitis

Licensed patents relate to hep- arin-binding epidermal growth factor-like growth factor and therapies targeting anti-proliferative factor (9/6)

Adenosine
Therapeutics
LLC*

National Institutes of Health

License agreement

Adenosine got rights to adenosine antagonists for treating cancer

The antagonists also will be studied for improving the efficacy of vaccines; terms of the deal were not disclosed (9/12)

Adenosine
Therapeutics
LLC*

University of Massachusetts Medical School

License agreement

Adenosine got rights to technology for use in cardiac applications

The licensed patent is titled, "Adenosine as a positive inotrope in the compromised heart"; terms of the deal were not disclosed (9/12)

Advanced Cell
Technology Inc.
(OTC BB:ACTC)

WiCell Research Institute

Collaboration

To jointly distribute to U.S. scientists a range of new cell lines

The deal is contigent on the U.S. federal government's recognition and funding of the cell lines (9/12)

Affymetrix
Inc.
(AFFX)

Peter MacCallum
Cancer Centre
(Australia)

Collaboration

Five-year deal focused on translational research projects

Researchers will use Affymetrix GeneChip microarray technology to analyze genomic information; the initial focus is ovarian cancer and carcinomas of unknown origin (9/27)

Affymetrix
Inc.
(AFFX)

Partners HealthCare

Collaboration

Deal to develop micro- array-based diagnostics for complex diseases

The three-year translational research collaboration targets diseases such as newborn hearing loss, autism and hypertrophic cardiomyopathy (9/7)

Alkermes
Inc.
(ALKS)

Rensselaer Polytechnic Institute

License agreement

Alkermes got exclusive rights to a family of novel opioid receptor compounds

Rensselaer gets an up-front payment and is eligible to receive milestone and royalty payments; the program targets various central nervous system disorders (10/5)

BioLineRx
Ltd.*
(Israel)

Ben-Gurion University of the Negev and Clalit Health Services (both of Israel)

License agreement

BioLineRx got rights to BL-3030, an antisense drug for treating inflammatory diseases

Terms of the exclusive, worldwide license agreement were not disclosed (9/8)

CardioVascular
BioTherapeutics
Inc.
(OTC BB:CVBT)

Orthopaedic Education and Research Institute of Southern California

Collaboration

Deal to conduct a feasibility study in patients with chronic back pain caused by degenerative disc disease

The goal is to determine if back pain is related to poor blood flow and decreased nutrition of the discs in the lower back (9/13)

Celldex
Therapeutics
Inc.*

Ludwig Institute for Cancer Research

Collaboration

Multityear deal focused on a series of tumor- associated antigens (TAAs)

They plan to develop immuno-therapies using Celldex's APC targeting monoclonal antibodies and LICR's TAAs; LICR has rights to use resulting products in clinical trials (10/23)

Cobra Bio-
manufacturing
plc
(UK;
AIM:CBF)

U.S. Naval
Medical Research
Center

CRADA

Cobra will construct and test a vaccine against malaria

Cobra will use its ORT-VAC oral vaccine delivery technology in the effort; terms of the deal were not disclosed (10/16)

Cumbre
Pharmaceuticals
Inc.*

The Global Alliance for TB Drug Development

Collaboration

Deal to jointly pursue development of new drugs against tuberculosis

The focus is on two classes of multifunctional antibodies; the TB Alliance will have rights to resulting products in TB and certain other diseases; Cumbre will have rights in other infectious diseases (9/27)

Dyax Corp.
(DYAX)

Commonwealth Scientific and Industrial Research Organisation (Australia)

Collaboration

Deal to discover and develop therapeutic antibodies for treating cancer

Dyax will screen clinical candi- dates, and CSIRO will provide reagents and in vitro assays, as well as certain preclinical development work; Dyax will have the option to advance resulting anti- body leads into the clinic (11/29)

Edison
Pharmaceuticals
Inc.*

Institute of Vision, University of Sao Paulo (Brazil)

Collaboration

Deal to develop drugs targeting Leber's hereditary optic neuropathy, which leads to blindness

The institute and its research consortium will evaluate Edison drugs that target inherited mitochondrial diseases; terms were not disclosed (10/2)

Evogenix Ltd.
(Australia; ASX:EGX)

National Institutes of Health

CRADA

Deal to develop anti- antibody therapies against PAMP, an angiogenesis cancer target

EvoGenix will provide antibodies against PAMP; National Cancer Institute researchers will test the antibodies; further details were not disclosed (11/2)

Galapagos NV
(the Netherlands;
Euronext:GLPG)

Cystic Fibrosis Foundation Therapeutics Inc.

Collaboration extension

They extended for 15 months a target discovery deal in cystic fibrosis

Galapagos unit BioFocus DPI gets research fees of €0.8M; their alliance began in April 2005 (11/22)

Galapagos NV
(the Netherlands;
Euronext:GLPG)

Institute for OneWorld Health

Collaboration

Deal focused on development of drugs for treating diarrheal diseases

Galapagos unit BioFocus DPI will work to identify drug candidates for the program; it is entitled to more than €3M over the 2.5-year contract (9/6)

Genzyme Corp.
(GENZ)

Medicines for Malaria Venture (Switzerland) and the Broad Institute

Collaboration

They expanded collaboration to discover and develop therapeutics for treating malaria

There are four early discovery projects in their portfolio; MMV will get access to resulting products on a royalty-free basis (10/18)

Hana
Biosciences
Inc.
(HNAB)

Albert Einstein College of Medicine

License agreement

Hana got rights to Menadione, a preclinical product for skin rash associated with use of epidermal growth factor receptor inhibitors

The rights are exclusive and worldwide, and include sublicensing rights; the college would get royalties on resulting sales (10/16)

Humanyx
Pte. Ltd.*
(Singapore)

Genome Institute of Singapore

Collaboration

Deal to develop antibody therapies against the H5N1 virus

GIS gets rights to use Humanyx's phage library in the effort; terms of the deal were not disclosed (11/28)

Interleukin
Genetics Inc.
(AMEX:ILI)

Yonsei University (South Korea)

Collaboration

Deal to study the role of genetics in spine fractures

The focus is exploring potential links between interleukin-1 gene variations and spine fractures in postmenopausal Korean women (9/7)

Introgen
Therapeutics Inc.
(INGN)

University of Texas M.D. Anderson Cancer Center

License agreement

Introgen got rights to nanoparticle-based delivery technology

The cancer-directed technology is based on delivery of large molecules using nanoparticle delivery complexes; terms of the deal were not disclosed (11/16)

Introgen
Therapeutics
Inc.
(INGN)

University of Texas M.D. Anderson Cancer Center

License agreement

Introgen got rights to patent applications covering combinationcancer therapies

The patents are directed at the use of Introgen's Advexin with epidermal growth factor receptor inhibitors; Introgen sponsors research at the center; license terms were not disclosed (11/3)

InViragen LLC*

Centers for Disease Control and Prevention

License agreement

InViragen got rights to vaccine technology applicable to multiple viral diseases

Targets include dengue fever and West Nile disease; terms of the exclusive license were not disclosed (9/15)

Lentigen
Corp.*

University of Pennsylvania

Agreement

To develop the company's lentiviral vector for clinical gene therapy research

Terms of the deal were not disclosed; the focus is immuno-therapy approaches in cancer indications (9/7)

Lexicon
Genetics Inc.
(LEXG)

U.S. Army Medical Research & Materiel Command

Research program

Deal to develop drugs for spinal muscular atrophy was extended an additional year

Lexicon will get $2.5M in funding for the one- year extended term; it has a deal with the SMA Foundation for development of resulting drug candidates (10/11)

Lux
Biosciences
Inc.*

National Institutes of Health

License agreement

Lux got rights to LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye

Pivotal trials for prevention of rejection in corneal transplantation were expected to begin in early 2007; terms of the worldwide deal were not disclosed (11/7)

Lux
Biosciences
Inc.*

Rutgers University

License agreement

Lux gained access to Rutger's polyarylate patent estate

Lux plans to use the technology in the treatment of eye diseases; terms of the deal were not disclosed (9/13)

MethylGene Inc.
(Canada;
TSX:MYG)
and EnVivo
Pharmaceuticals
Inc.*

CHDI Inc.

Agreement

CHDI is supporting the companies' program to develop histone deacetylase inhibitors for Huntington's disease

CHDI is providing up to $1.5M in initial funding, and providing research support; MethylGene and EnVivo retain commercial rights (11/16)

MorphoSys
AG
(Germany;
FSE:MOR)

Burnham Institute for Medical Research

Agreement

The institute will use antibody technology from MorphoSys to identify and validate target molecules

MorphoSys retains commercialization rights for all emerging antibodies, in research and in therapeutic or diagnostic applications; terms of the deal were not disclosed (11/28)

Nastech
Pharmaceutical
Co. Inc.
(NSTK)

City of Hope

License agreement

Nastech got rights to Dicer- substrate RNA interference technology

Nastech's rights are exclusive for five targets; broader rights are nonexclusive; terms of the deal were not disclosed (11/8)

Novavax Inc.
(NVAX)

Centers for Disease Control and Prevention

CRADA

The CDC will evaluate the company's H5N1 pandemic influenza vaccine candidate

Research will include preclinical testing against live bird flu virus (10/31)

Omrix Bio-
pharmaceuticals
Inc.
(OMRI)

National Institute of Allergy and Infectious Diseases

CRADA

Deal to to develop new antibody- based therapeutics for treating avian influenza

They will use the NIAID's expertise in influenza and vaccines and Omrix's capabilities in man- ufacturing and antibody development; terms of the deal were not disclosed (10/9)

Open
Biosystems
Inc.*

National Cancer Institute

Agreement

The NCI will evaluate the effectiveness of certain OBI technology

The NCI will test lentiviral microRNA-adapted short hairpin RNA technology in 135 specifically targeted cancer genes (10/30)

Orion
Genomics*

Mayo Clinic

Collaboration

Deal to study the clinical utility of Orion's breast cancer screening tests

The technology is based on epigenetic biomarkers; they also will use it in more than a dozen other cancer types (11/19)

Oxford
BioMedica
plc
(UK; LSE:OXB)

The Foundation Fighting Blindness

Collaboration

Deal to develop gene therapy products for treating eye diseases; it follows a 2003 deal for preclinical development of RetinoStat

The first product in the expanded deal is StarGen for treating Stargardt disease; FFB and investors will make an up-front payment to Oxford, and purchase up to $3.9M in stock; they would get a royalty on any resulting sales (10/2)

Pain
Therapeutics
Inc.
(PTIE)

Albert Einstein College of Medicine

License agreement

Nastech got rights to a radiolabeled monoclonal antibody technology

The college gets an up-front fee and may get up to $3.5M in milestone payments, as well as a 4% sales royalty; rights are exclusive in oncology and infectious disease indications (11/8)

Phase
Bioscience
Inc.*

Duke University

License agreement

PhaseBio got certain rights to technology associated with drug delivery based on ELP technology

PhaseBio has worldwide rights to use the technology with its drugs, and in third-party arrangements; terms of the deal were not disclosed (11/8)

Raptor
Pharmaceuticals
Corp.
(OTC BB:RPTP)

Washington University

License agreement

Raptor got rights to use Mesd reagents in the treatment of cancer and osteoporosis

Mesd is a chaperone protein that may be useful in the regulation of the LRP5 and LRP6 receptors; terms of the worldwide deal were not disclosed (11/6)

Senetek plc
(OTC
BB:SNTKY)

Institute of Bioorganic Chemistry of the Polish Academy of Sciences

License agreements

Senetek got rights to an anticancer agent and to three com- pounds for treatment of skin aging

The first technology targets brain cancer through RNA interference; the institute is entitled to royalties on resulting sales (11/7)

Somanta
Pharmaceuticals
Inc.
(OTC BB:SMPM)

University of Bradford (UK)

Collaboration

Somanta got rights to discoveries in certain areas of cancer research at the university

As part of the deal, the university's Institute for Cancer Therapeutics will continue development work on two Somanta pre-clinical cancer drugs (9/19)

Stem Cell
Innovations Inc.
(OTC BB:SCLL)

Massachusetts Eye and Ear Infirmary

Collaboration

MEEI will evaluate SCI's PluriCells technology in the formation of human tissues implicated in hearing loss

MEEI gets access to the pluri- potent stem cell technology; SCI will get nonexclusive rights to resulting intellectual property (10/10)

Stem Cell
Innovations Inc.
(OTC BB:SCLL)

University of Twente (the Netherlands)

Collaboration

Deal to explore the bone-forming properties of SCI's PluriCells technology

The university gets access to the pluripotent stem cell technology; SCI will get nonexclusive rights to resulting intellectual property (10/3)

Synairgen plc(UK; LSE:SNG)

University of Southampton (UK)

License agreement

Synairgen got exclusive rights to peptide technology directed against asthma

The peptide is believed to suppress the effects of both interleukin-4 and IL-13; terms of the deal were not disclosed (11/15)

Transition
Therapeutics Inc.
(Canada; TSX:TTH)

Juvenile Diabetes Research Foundation

Partnership

The JDRF will support development of Transition's diabetes regenerative product, GLP1-I.N.T.

Transition is eligible to receive milestone-driven payments of up to $4M over two years; further terms were not disclosed (9/13)

Trophos SA*
(France)

CHDI Inc.

Collaboration extension

They extended deal to discover and develop drugs for Huntington's disease

They will build on earlier work on compounds that confer a survival benefit on primary striatal neurons; Trophos retains rights to resulting candidates (9/21)

U.S Genomics
Inc.*

Lahey Clinic

Agreement

Deal to study the rolemicroRNAs play in the development of urological cancers

The objective is to develop more accurate prognoses for bladder and prostate cancers (10/17)

Vical Inc.
(VICL)

Six research institutions

License agreement

The institutions got rights to DNA delivery technology, for use in product development

Licenses were granted to Fred Hutchinson Cancer Research Center, Texas Tech University Health Sciences Center, University of Iowa, University of Notre Dame, University of Pittsburgh and University of Washington (9/19)

Viropro Inc.
(OTC BB:VPRO)

National Research Council-Biotechnology Research Institute

License agreement

Viropro got rights to use the NRC's inducible expression systems

The technology will be used in the production of recombinant human interferon beta; terms were not disclosed; licenses covering other proteins were being negotiated (10/26)


Notes:

This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.

CRADA = Cooperative Research and Development Agreement.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange;

LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.

No Comments